Literature DB >> 6747752

DTP reactions and serologic response with a reduced dose schedule.

R M Barkin, J S Samuelson, L P Gotlin.   

Abstract

In a double-blind study, infants received standard (0.5 ml) or modified (0.25 ml) doses of DTP vaccine for the primary series of three immunizations administered at 2, 4, and 6 months of age and the booster immunization at 18 months. Side effects and antibody responses were determined in 80 children who completed the primary series and 73 who received the booster. The modified regimen was associated with significantly reduced febrile reactions and behavioral changes after the primary series and booster inoculation: 63.2% of those who received the standard dose had febrile reactions, compared to 42.3% who received the modified dose during the primary series; a similar difference was observed with the booster. Only 47.2% of the reduced dosage recipients demonstrated marked behavioral changes, and 62.4% of the standard vaccine recipients had comparable reactions. An even larger difference (33.3% vs 64.7%) was noted at the time of the booster. The modified vaccine produced a local reaction incidence of 58.5%, compared to 72.6% in the control population during the primary immunization series; no differences were noted in local reactions with the booster dose. All patients had serologic evidence of protective titers against diphtheria and tetanus. After the primary immunization series, 97.6% and 97.3% of the infants given the modified and standard doses, respectively, had pertussis agglutinin titers of greater than or equal to 1:16. One patient who received the standard dosage had a titer of less than 1:16 one month after the booster immunization, whereas all those given the modified dose had titers greater than or equal to 1:16. Geometric mean titers of pertussis agglutinins were higher in the standard vaccine recipients after the primary series, but were similar in the two study groups before and after the 18-month immunization.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6747752     DOI: 10.1016/s0022-3476(84)80111-0

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  9 in total

1.  Pertussis: the disease and the vaccine.

Authors:  R Gold
Journal:  Can Fam Physician       Date:  1986-01       Impact factor: 3.275

2.  Fractional doses of DPT vaccine.

Authors:  A K Leung
Journal:  Can Med Assoc J       Date:  1985-01-15       Impact factor: 8.262

3.  Validation of the combined toxin-binding inhibition test for determination of neutralizing antibodies against tetanus and diphtheria toxins in a vaccine field study in Viet Nam.

Authors:  H A Hong; N T Ke; T N Nhon; N D Thinh; J W van der Gun; J T Hendriks; J G Kreeftenberg
Journal:  Bull World Health Organ       Date:  1996       Impact factor: 9.408

4.  Dose-response effects in immunizations with keyhole limpet haemocyanin and rabies vaccine: shift in some immunodeficiency states.

Authors:  K Korver; E W Boeschoten; R T Krediet; G van Steenis; P T Schellekens
Journal:  Clin Exp Immunol       Date:  1987-11       Impact factor: 4.330

5.  Fractional doses of DPT vaccine.

Authors:  J Cameron
Journal:  CMAJ       Date:  1986-01-01       Impact factor: 8.262

6.  The search for a safer pertussis vaccine.

Authors:  B Goldman
Journal:  CMAJ       Date:  1989-01-01       Impact factor: 8.262

7.  Fractional doses of DPT vaccine.

Authors:  J R Waters
Journal:  Can Med Assoc J       Date:  1985-06-01       Impact factor: 8.262

8.  Simultaneous administration of diphtheria-tetanus-pertussis-polio and hepatitis B vaccines in a simplified immunization program: immune response to diphtheria toxoid, tetanus toxoid, pertussis, and hepatitis B surface antigen.

Authors:  P Coursaget; B Yvonnet; E H Relyveld; J L Barres; I Diop-Mar; J P Chiron
Journal:  Infect Immun       Date:  1986-03       Impact factor: 3.441

9.  MenAfriVac as an Antitetanus Vaccine.

Authors:  Ray Borrow; Yuxiao Tang; Ahmadu Yakubu; Prasad S Kulkarni; F Marc LaForce
Journal:  Clin Infect Dis       Date:  2015-11-15       Impact factor: 9.079

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.